IP Library Granted Patent US 10,875,834
Granted Patent B2
US 10,875,834 · App. 16/318,590 · Granted Dec 29, 2020

Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives

Inventors: Martin K. Safo (Richmond, VA); Guoyan Xu (Richmond, VA); Yan Zhang (Richmond, VA); Osheiza Abdulmalik (Richmond, VA)
Assignees: Virginia Commonwealth University; The Children's Hospital of Philadelphia
C07D307/46A61P7/00A61P43/00C07D417/04C07F9/65515
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,875,834
App. No.
16/318,590
Granted
Dec 29, 2020
Kind
B2
Abstract

Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.

Claims (24)

1. A prodrug or protected form of 5-hydoxymethyl-2-furfural (5-HMF) with a generic formula:

where:

X is R 12 —O—· where R 12 is alkyl or aryl, and the bond marked with * bonds directly to CH 2 of Formula I;

Y is

where R is alkyl, and where the bond marked with * bonds directly to carbon at position 2 of the furan ring of Formula I;

and

Z is H, OH, alkyl, aryl, O-alkyl, O-aryl or O-heteroaryl.

2. A method of treating or prophylactically treating sickle cell disease in a subject in need thereof, comprising

administering to the subject a therapeutically effective amount of a prodrug or protected form of 5-hydoxymethyl-2-furfural (5-HMF) with a generic formula:

where:

X is R 12 —O—· where R 12 is alkyl or aryl, and the bond marked with * bonds directly to CH 2 of Formula I;

Y is

where R is alkyl, and where the bond marked with * bonds directly to carbon at position 2 of the furan ring of Formula I;

and

Z is H, OH, alkyl, aryl, O-alkyl, O-aryl or O-heteroaryl.

3. A method of treating or prophylactically treating hypoxia in a subject in need thereof, comprising

administering to the subject a therapeutically effective amount of a prodrug or protected form of 5-hydoxymethyl-2-furfural (5-HMF) with a generic formula:

where:

X is R 12 —O—· where R 12 is alkyl or aryl, and the bond marked with * bonds directly to CH 2 of Formula I

Y is

where R is alkyl, and where the bond marked with * bonds directly to carbon at position 2 of the furan ring of Formula I;

and

Z is H, OH, alkyl, aryl, O-alkyl, O-aryl or O-heteroaryl.

4. The prodrug or protected form of 5-hydroxymethyl-2-furfural (5-HMF) having the structure

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 15, 2023
From: VIRGINIA COMMENWEALTH UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062760/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2019
From: SAFO, MARTIN K.; XU, GUOYAN; ZHANG, YAN; ABDULMALIK, OSHEIZA
To: VIRGINIA COMMONWEALTH UNIVERSITY; THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Reel/Frame 048059/0600 →
Continuity (3)
Provisional Application 62366250 · Jul 25, 2016
Provisional Application 62365563 · Jul 22, 2016
Related Publication 20190256483A1 · Aug 22, 2019